AP2745A - Reducing interference between oil-containing adjuvants and surfactant-containing antigens - Google Patents

Reducing interference between oil-containing adjuvants and surfactant-containing antigens

Info

Publication number
AP2745A
AP2745A AP2008004352A AP2008004352A AP2745A AP 2745 A AP2745 A AP 2745A AP 2008004352 A AP2008004352 A AP 2008004352A AP 2008004352 A AP2008004352 A AP 2008004352A AP 2745 A AP2745 A AP 2745A
Authority
AP
ARIPO
Prior art keywords
surfactant
oil
reducing interference
adjuvants
antigens
Prior art date
Application number
AP2008004352A
Other languages
English (en)
Inventor
Mario Contorni
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37684892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2745(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0515906.6A external-priority patent/GB0515906D0/en
Priority claimed from GB0522599A external-priority patent/GB0522599D0/en
Priority claimed from GB0523923A external-priority patent/GB0523923D0/en
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of AP2745A publication Critical patent/AP2745A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AP2008004352A 2005-08-02 2006-08-02 Reducing interference between oil-containing adjuvants and surfactant-containing antigens AP2745A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0515906.6A GB0515906D0 (en) 2005-08-02 2005-08-02 Mixtures of antigen and adjuvant
GB0522599A GB0522599D0 (en) 2005-11-04 2005-11-04 Adjuvants and antigens
GB0523923A GB0523923D0 (en) 2005-11-24 2005-11-24 Adjuvants and antigens

Publications (1)

Publication Number Publication Date
AP2745A true AP2745A (en) 2013-09-30

Family

ID=37684892

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004352A AP2745A (en) 2005-08-02 2006-08-02 Reducing interference between oil-containing adjuvants and surfactant-containing antigens

Country Status (21)

Country Link
US (1) US20090220547A1 (pl)
EP (1) EP1909830B1 (pl)
JP (1) JP2009503051A (pl)
KR (1) KR101321732B1 (pl)
CN (1) CN103690945A (pl)
AP (1) AP2745A (pl)
AT (1) ATE526036T1 (pl)
AU (1) AU2006274647B2 (pl)
BR (1) BRPI0614254A2 (pl)
CA (1) CA2617362A1 (pl)
CY (1) CY1112149T1 (pl)
DK (1) DK1909830T3 (pl)
EA (1) EA014314B1 (pl)
IL (1) IL189102A (pl)
MX (1) MX2008001527A (pl)
NO (1) NO20081033L (pl)
NZ (1) NZ565512A (pl)
PL (1) PL1909830T3 (pl)
PT (1) PT1909830E (pl)
SI (1) SI1909830T1 (pl)
WO (1) WO2007015167A2 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102257149B (zh) 2008-08-28 2013-12-25 诺华股份有限公司 由超产酵母生产角鲨烯
US9381242B2 (en) 2011-03-11 2016-07-05 The Chemo—Sero—Therapeutic Research Institute Adjuvant composition containing citrulline
FR3002454B1 (fr) * 2013-02-26 2015-04-10 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion
US9968673B2 (en) 2013-02-26 2018-05-15 Commissariat á l'ènergie atomique et aux ènergies alternatives Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent
FR3043558B1 (fr) * 2015-11-18 2017-12-29 Commissariat Energie Atomique Composition immunogene sous forme d'emulsion comprenant deux phases dispersees, l'une comprenant un antigene et l'autre comprenant un agent immunostimulant
EP3377114B1 (fr) * 2015-11-18 2020-07-08 Commissariat à l'Énergie Atomique et aux Énergies Alternatives Composition immunogène sous forme d'émulsion comprenant deux phases dispersées, l'une comprenant un antigène et l'autre comprenant un agent immunostimulant
EP3903815A4 (en) 2018-12-24 2022-09-28 Grand Theravac Life Science (Nanjing) Co., Ltd. Pharmaceutical preparation for treating hepatitis b, preparation method therefor and use thereof
TW202245835A (zh) * 2021-02-04 2022-12-01 美商默沙東有限責任公司 用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3435112A (en) * 1966-06-21 1969-03-25 Norden Lab Inc Repository vaccine and method of preparing the same
WO1998043670A2 (en) * 1997-04-01 1998-10-08 Ribi Immunochem Research, Inc. Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
WO2000003744A2 (en) * 1998-07-14 2000-01-27 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199565A (en) * 1979-03-26 1980-04-22 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5709879A (en) * 1990-06-29 1998-01-20 Chiron Corporation Vaccine compositions containing liposomes
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
ATE353225T1 (de) * 1995-11-30 2007-02-15 Chemo Sero Therapeut Res Inst Öladjuvierter impfstoff und verfahren zu seiner herstellung
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CN101926993B (zh) * 1998-10-16 2013-12-04 史密丝克莱恩比彻姆生物有限公司 佐剂系统及疫苗
PL203951B1 (pl) * 1999-04-19 2009-11-30 Smithkline Beecham Biolog Kompozycja adiuwantowa, kompozycja szczepionki oraz sposób jej wytwarzania, szczepionka oraz zastosowanie
MXPA02003069A (es) * 1999-09-24 2002-09-30 Smithkline Beecham Biolog Vacuna intranasal contra el virus de la influenza..
JP2001151699A (ja) * 1999-11-29 2001-06-05 Nippon Surfactant Kogyo Kk 動物用ワクチンのオイルアジュバント
KR20010105882A (ko) * 2000-05-19 2001-11-29 배길훈 스티어링 칼럼 구조
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
EP1322292B1 (en) * 2000-09-28 2007-01-03 Novartis Vaccines and Diagnostics, Inc. Microparticle compositions and methods for the manufacture thereof
EP1256804B1 (en) * 2001-05-09 2012-09-26 Bio Merieux HBcAg expression and diagnostic and therapeutic uses
TWI228420B (en) * 2001-05-30 2005-03-01 Smithkline Beecham Pharma Gmbh Novel vaccine composition
EA012212B1 (ru) * 2005-02-16 2009-08-28 Новартис Вэксинес Энд Дайэгностикс, Инк. Адъювантная композиция, содержащая фосфат алюминия и 3d-mpl
WO2006113528A2 (en) * 2005-04-18 2006-10-26 Novartis Vaccines And Diagnostics Inc. Expressing hepatitis b virus surface antigen for vaccine preparation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3435112A (en) * 1966-06-21 1969-03-25 Norden Lab Inc Repository vaccine and method of preparing the same
WO1998043670A2 (en) * 1997-04-01 1998-10-08 Ribi Immunochem Research, Inc. Aqueous immunologic adjuvant compositions of monophosphoryl lipid a
WO2000003744A2 (en) * 1998-07-14 2000-01-27 American Cyanamid Company Adjuvant and vaccine compositions containing monophosphoryl lipid a

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; HASHIMOTO, SATORU ET AL.: "Ether-type surfactant - free oil adjuvants and animal vaccines containing the adjuvants" XP002418606 retrieved from STN Database accession no. 2001:403420 abstract & JP 2001 151699 A (NIHON SURFACTANTS INDUSTRY CO., LTD., JAPAN; MICROBIOCHEMICAL RESEARCH) 5 June 2001 (2001-06-05) *
TRAQUINA P ET AL: "MF59 ADJUVANT ENHANCES THE ANTIBODY RESPONSE TO RECOMBINANT HEPATITIS B SURFACE ANTIGEN VACCINE IN PRIMATES" JOURNAL OF INFECTIOUS DISEASES, CHICAGO, IL, US, vol. 174, no. 6, 1996, pages 1168-1175, XP000971687 ISSN: 0022-1899 *

Also Published As

Publication number Publication date
NO20081033L (no) 2008-02-27
PT1909830E (pt) 2011-11-24
BRPI0614254A2 (pt) 2011-03-15
EA014314B1 (ru) 2010-10-29
US20090220547A1 (en) 2009-09-03
IL189102A0 (en) 2008-08-07
ATE526036T1 (de) 2011-10-15
CN103690945A (zh) 2014-04-02
WO2007015167A2 (en) 2007-02-08
AU2006274647B2 (en) 2013-01-10
KR101321732B1 (ko) 2013-10-29
SI1909830T1 (sl) 2012-01-31
PL1909830T3 (pl) 2012-02-29
KR20080038384A (ko) 2008-05-06
JP2009503051A (ja) 2009-01-29
DK1909830T3 (da) 2011-12-19
EP1909830A2 (en) 2008-04-16
CY1112149T1 (el) 2015-11-04
EA200800509A1 (ru) 2008-10-30
CA2617362A1 (en) 2007-02-08
AU2006274647A1 (en) 2007-02-08
EP1909830B1 (en) 2011-09-28
IL189102A (en) 2011-09-27
WO2007015167A3 (en) 2007-05-03
MX2008001527A (es) 2008-04-04
NZ565512A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
IL222922A (en) Antibodies against neurophilin-1 and their use
PT1599504E (pt) Anticorpo modificado
IL190472A0 (en) Anti-glypican-3 antibody
HRP20130494T1 (en) Anti-ilt7 antibody
IL185366A0 (en) Antibody
IL189102A0 (en) Reducing interference between oil-containing adjuvants and surfactant- containing antigens
IL192119A0 (en) Novel cancer -associated antigen
AP2191A (en) Methods of reducing nematode damage.
IL185781A0 (en) Antibodies against candida antigens
GB0502298D0 (en) Well assembly and method
GB0329178D0 (en) Surfactant
EP1806121A4 (en) PREPARATION AGAINST TRUST
GB2428042B (en) P gingivalis vaccine
IL215527A (en) Methods will notice training
ZA200801004B (en) Reducing interference between oil-containing adjuvants and surfactant-containing antigens
ZA200707838B (en) Antibodies against Candida antigens
EP1780221A4 (en) ANTI-SYNOVIOLIN ANTIBODY
GB2417709B (en) Document
EP1820615A4 (en) MECHANICAL RABOT
GB0418444D0 (en) Montage method
GB0418415D0 (en) Antibody
AP2007004280A0 (en) Immunological adjuvant emulsion
GB0507672D0 (en) Adjuvant
GB0523923D0 (en) Adjuvants and antigens
GB0522599D0 (en) Adjuvants and antigens